Eyeworld CME Supplements

EW SEP 2017 - Supported by unrestricted educational grants from Allergan, Shire Pharmaceuticals, TearLab, and TearScience

This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.

Issue link: http://cmesupplements.eyeworld.org/i/863394

Contents of this Issue

Navigation

Page 7 of 7

CME questions (circle the correct answer) 8 Copyright 2017 ASCRS Ophthalmic Corporation. All rights reserved. The views expressed here do not necessarily reflect those of the editor, editorial board, or the publisher, and in no way imply endorsement by EyeWorld or ASCRS. To take this test online and claim credit, go to bit.ly/2vfjjgk or complete the test below and fax, mail, or email it in. 1. A 55-year-old woman with a history of dry eye tried artificial tears, cyclosporine, and lifitegrast but still had symptoms of foreign body sensation and her eyes were red. Tear osmolarity was elevated (375 mOsms/L), MMP-9 was positive, the tear film was foamy, and meibum was thickened. What would be the best course of management? a. Represcribe cyclosporine and/or lifitegrast and stress compliance b. Consider topical antihistamine therapy for allergic conjunctivitis c. Recommend warm compresses and lid scrubs and possibly consider automated thermal pulsation d. Increase preservative-free artificial tears to every hour and prescribe ointment for nighttime 2. A 48-year-old man with intermittent foreign body sensation, fluctuating vision, dryness, mild itching, and redness was diagnosed with dry eye, but artificial tears provided no relief. He had mild inferior punctate epithelial erosions, osmolarity was normal, and MMP-9 testing had positive results. Which of the following would be most likely to yield useful information at this point? a. Fluorescein tear breakup time b. Schirmer's c. Tear IgE testing d. All of the above 3. If a positive tear osmolarity and negative MMP-9 testing confirm the presence of dry eye, the clinician next needs to: a. Ask the patient to complete a SPEED questionnaire b. Perform thermal pulsation c. Prescribe preservative-free artificial tears and a T-cell modulator d. Determine whether meibomian gland disease is present 4. ________________ was the first FDA-approved prescription anti-inflammatory drug to treat the signs and symptoms of dry eye. a. Azelastine hydrochloride b. Lifitegrast c. Cyclosporine 0.05% d. Topical azithromycin 5. A 67-year-old patient with cataracts was contact lens intolerant and her vision was slightly hazy. Tear osmolarity was 322 and 311 mOsms/L, and MMP-9 was positive in both eyes. She had significant staining and significant meibomian gland dropout. Her mean keratometry measurement was 44.2, and she had 1.18 D of cylinder. She was treated with artificial tears, a short course of steroids, oral omega-3 fatty acids, and thermal pulsation. Which additional treatment would likely be prescribed? a. T-cell modulator b. Alcaftadine ophthalmic solution 0.25% c. Oral doxycycline d. Gatifloxacin ophthalmic solution To claim credit, please fax the test and fully completed form by February 28, 2018, to 703-547-8842, email to GPearson@ascrs.org, or mail to: EyeWorld, 4000 Legato Road, Suite 700, Fairfax, VA 22033, Attn: September 2017 CME Supplement ASCRS Member ID (optional): First/Last Name/Degree: Practice: Address: City, State, Zip, Country: Phone: Email: Please print email address legibly, as CME certificate will be emailed to the address provided. The third refractive surface: Improving surgical outcomes with advanced diagnostics and therapeutics

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld CME Supplements - EW SEP 2017 - Supported by unrestricted educational grants from Allergan, Shire Pharmaceuticals, TearLab, and TearScience